Jordan earned his PhD degree from the University of Oklahoma Health Sciences Center as a National Institute on Drug Abuse Fellow. He generated supporting data packages for collaborating Big Pharma companies utilizing standard rodent models of operant conditioning. He was recruited by Roche Pharmaceuticals and relocated to Palo Alto, California in 2002, to continue working as a part of the Neurobehavioral Unit developing rodent and non-human primate (NHP) models of cognition and psychiatric diseases. Before leaving Roche, Jordan helped to create the foundation of the NHP screening cascade that successfully advanced at least two cognitive enhancer targets. Over the subsequent +15 years, Jordan has worked for companies at all levels and sizes, including non-profit biomedical foundations and small Biotech start-ups. One of the most interesting of these was focused on establishing the feasibility of using nasal administration as a means to deliver therapeutic small molecules and peptides directly to the central nervous system, bypassing the “blood-brain barrier”. At least one of these molecules advanced to the clinical stage during his role as Director of Preclinical Science, providing the opportunity to follow drug discovery across the “translational gap”. Over nearly 20 years in Industry, Jordan has work on discovering or repurposing compounds for nearly every major therapeutic area, with particular emphasis on CNS, Pain, Respiratory, Inflammation / Autoimmune, and Metabolic diseases. Outside of work, Jordan enjoys visiting out of the way locations (particularly, tropical ones), SCUBA diving (certified Rescue diver) and playing golf. He also enjoys most games of skill, particularly poker.
Are you Recursion ready?
Join our passionate, innovative team—and help us realize our goal of 100 treatments by 2025.